Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

被引:499
|
作者
Ank, N
West, H
Bartholdy, C
Eriksson, K
Thomsen, AR
Paludan, SR
机构
[1] Aarhus Univ, Inst Med Microbiol & Immunol, DK-8000 Aarhus C, Denmark
[2] Univ Copenhagen, Inst Med Microbiol & Immunol, Copenhagen, Denmark
[3] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden
关键词
D O I
10.1128/JVI.80.9.4501-4509.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Type III interferons (IFNs) (interleukin-28/29 or lambda interferon [IFN-lambda]) are cytokines with IFN-like activities. Here we show that several classes of viruses induce expression of IFN-lambda 1 and -lambda 2/3 in similar patterns. The IFN-lambda s were-unlike alpha/beta interferon (IFN-alpha/beta)-induced directly by stimulation with IFN-alpha or -lambda, thus identifying type III IFNs as IFN-stimulated genes. In vitro assays revealed that IFN-lambda s have appreciable antiviral activity against encephalomyocarditis virus (EMCV) but limited activity against herpes simplex virus type 2 (HSV-2), whereas IFN-alpha potently restricted both viruses. Using three murine models for generalized virus infections, we found that while recombinant IFN-alpha reduced the viral load after infection with EMCV, lymphocytic choriomeningitis virus (LCMV), and HSV-2, treatment with recombinant IFN-lambda in vivo did not affect viral load after infection with EMCV or LCMV but did reduce the hepatic viral titer of HSV-2. In a model for a localized HSV-2 infection, we further found that IFN-lambda completely blocked virus replication in the vaginal mucosa and totally prevented development of disease, in contrast to IFN-alpha, which had a more modest antiviral activity. Finally, pretreatment with IFN-lambda enhanced the levels of IFN-lambda in serum after HSV-2 infection. Thus, type III IFNs are expressed in response to most viruses and display potent antiviral activity in vivo against select viruses. The discrepancy between the observed antiviral activity in vitro and in vivo may suggest that IFN-lambda exerts a significant portion of its antiviral activity in vivo via stimulation of the immune system rather than through induction of the antiviral state.
引用
收藏
页码:4501 / 4509
页数:9
相关论文
共 36 条
  • [21] Porcine interferon lambda 3 (IFN-λ3) shows potent anti-PRRSV activity in primary porcine alveolar macrophages (PAMs)
    Jun Zhao
    Ling Zhu
    Lei Xu
    Jianbo Huang
    Xiangang Sun
    Zhiwen Xu
    [J]. BMC Veterinary Research, 16
  • [22] IFN-γ establishes interferon-stimulated gene-mediated antiviral state against Newcastle disease virus in chicken fibroblasts
    Yang, Xin
    Arslan, Mehboob
    Liu, Xingjian
    Song, Haozhi
    Du, Mengtan
    Li, Yinu
    Zhang, Zhifang
    [J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (03) : 268 - 280
  • [23] Antiviral activity of bovine type III interferon against bovine viral diarrhea virus is greatly reduced in bovine turbinate cells due to limited expression of IFN lambda receptor 1 (IL-28Rα)
    Dassanayake, Rohana P.
    Menghwar, Harish
    Bickel, Kathryn A.
    Holthausen, David J.
    Ma, Hao
    Segunda, Fayna Diaz-San
    Rodriguez-Calzada, Monica
    Medina, Gisselle N.
    Attreed, Sarah
    Falkenberg, Shollie M.
    Kanipe, Carly
    Sacco, Randy E.
    de los Santos, Teresa
    Casas, Eduardo
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
    Diaz-San Segundo, Fayna
    Weiss, Marcelo
    Perez-Martin, Eva
    Koster, Marla J.
    Zhu, James
    Grubman, Marvin J.
    de los Santos, Teresa
    [J]. VIROLOGY, 2011, 413 (02) : 283 - 292
  • [25] Prophylactic and Therapeutic Treatment with IFN-lambda, a Novel Type III Interferon, Has Potent Efficacy in a Relapsing-Remitting EAE Model
    Sivakumar, Pallavur V.
    Lewis, Katherine E.
    Okada, Shannon
    Bontadelli, Kristen
    Kim, Kei
    Anderson, Monica
    Waggie, Kim
    Doyle, Sean E.
    [J]. NEUROLOGY, 2009, 72 (11) : A376 - A377
  • [26] Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model
    Bartlett, NW
    Buttigieg, K
    Kotenko, SV
    Smith, GL
    [J]. JOURNAL OF GENERAL VIROLOGY, 2005, 86 : 1589 - 1596
  • [27] Novel alpha interferon (IFN-α) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-α2b therapy in a subgenomic replicon system
    Escuret, Vanessa
    Martin, Amaury
    Durantel, David
    Parent, Romain
    Hantz, Olivier
    Trepo, Christian
    Menguy, Thierry
    Bottius, Emmanuel
    Dardy, Jerome
    Maral, Jean
    Escary, Jean Louis
    Zoulim, Fabien
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (12) : 3984 - 3991
  • [28] Expression of interferon-lambda receptor (IFN-λR1) in mononuclear phagocyte cells and effects of levels of newly discovered type III interferon lambda 4 (in-vitro study)
    Akhtar, H.
    Tran, S. My-Hang
    Hamming, O. Jensen
    Khalid, M.
    Terczyn'ska-Dyla, E.
    Hartmann, Rune
    Sadia, Hajra
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2015, 69 : 230 - 231
  • [29] The TLR3/IRF1/Type III IFN Axis Facilitates Antiviral Responses against Enterovirus Infections in the Intestine
    Su, Rui
    Shereen, Muhammad Adnan
    Zeng, Xiaofeng
    Liang, Yicong
    Li, Wen
    Ruan, Zhihui
    Li, Yongkui
    Liu, Weiyong
    Liu, Yingle
    Wu, Kailang
    Luo, Zhen
    Wu, Jianguo
    [J]. MBIO, 2020, 11 (06): : 1 - 19
  • [30] Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-γ as a Novel Antiviral Approach Against COVID-19
    Anjum, Faisal Rasheed
    Anam, Sidra
    Abbas, Ghazanfar
    Mahmood, Muhammad Shahid
    Rahman, Sajjad Ur
    Goraya, Mohsan Ullah
    Abdullah, Rana Muhammad
    Luqman, Muhammad
    Ali, Ashiq
    Akram, Muhammad Kamran
    Chaudhry, Tamoor Hamid
    [J]. VIRAL IMMUNOLOGY, 2021, 34 (05) : 321 - 329